Hepatitis C: latest news

Hepatitis C resources

Hepatitis C features

Hepatitis C in your own words

Hepatitis C news from aidsmap

More news

Hepatitis C news selected from other sources

  • Is There Any Good Reason Left to Delay Hepatitis C Treatment?

    Physicians increasingly argue that the best choice is to get rid of hepatitis C right away. But your insurance company may not agree. How risky is it to wait for treatment?

    17 April 2015 | Poz
  • EECA CAB positions in regards to Janssen, BMS, Gilead and ViiV policy

    EECA CAB (Community Advisory Board in Eastern Europe and Central Asia) has published its positions in regards to Janssen, BMS, ViiV and Gilead policy. The positions were developed on the results of the meetings with the companies during last year.

    09 March 2015 | EATG
  • Study: Door-to-door campaign linked hepatitis C patients to care

    Working on the streets in medically underserved Philadelphia neighborhoods, members of the Do One Thing program have been able to identify residents chronically infected with hepatitis C and help them overcome the hurdles that prevent people from being cured, according to a new study in the Journal of General Internal Medicine.

    16 February 2015 | Eurekalert Inf Dis
  • Healthcare: The race to cure rising drug costs

    The controversy over hepatitis C drug prices has highlighted the broader question of whether pharmaceutical companies can defend their premium pricing model in the world’s biggest healthcare market. It is a battle that big pharma risks losing, raising questions over the economic model of an industry that relies heavily on US profits to reward investors and finance new drugs.

    13 February 2015 | Financial Times
  • Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102

    Achillion Pharmaceuticals, Inc. today announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients.

    09 February 2015 | Achillion press release
  • Portugal agrees to treat 13,000 hepatitis C patients

    The Portuguese government has agreed to treat up to 13,000 people infected with hepatitis C in the next three years, Portuguese Minister of Health Paulo Macedo said on Friday.

    09 February 2015 | Xinhua
  • ChemSex and HCV transmission among UK MSM

    A recently published guide for health professionals (ChemSex & Hepatitis C), claiming to be based on c.500 conversations with MSM clients, offers an illuminating, ground-level account of one risk environment: events involving “ChemSex”, or the collective use of recreational drugs to enhance sexual experience. The authors claim that ChemSex parties are a growing HCV risk for MSM for three reasons: greater availability of certain non-injection drugs; increased injecting drug use; more widespread use of smartphone Apps and online “hooking-up” sites.

    03 February 2015 | BMJ Group blogs
  • Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries

    Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries presents a number of key strategies through real-world case studies and shows how strategies used to combat the AIDS epidemic can be—and have been—adapted to increase HCV treatment access.

    03 February 2015 | TAG
  • UNITAID publishes comprehensive review of detection and monitoring technologies for hepatitis C

    Diagnosis and screening currently too complex and expensive, but new options emerging.

    20 January 2015 | UNITAID press release
  • Hepatitis C drug delayed by NHS due to high cost

    The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected with the hepatitis C virus. The move by NHS England is unprecedented, because the NHS rationing body, Nice (the National Institute for Health and Care Excellence) has approved the drug. Nice says sofosbuvir is cost-effective, because it is a cure for people who would otherwise run up huge NHS bills.

    16 January 2015 | The Guardian
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.